Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 11/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863673 | 0.89 | LTA4H (0.59) | LTA4HHRH3CACNA1BCACNA1HKCNH2 | |
| SCHEMBL5863728 | 0.87 | LTA4H (0.51) | LTA4HHRH3CACNA1BCACNA1HKCNH2 | |
| SCHEMBL5863302 | 0.84 | LTA4H (0.47) | LTA4HHRH3CACNA1BCACNA1HKCNH2 | |
| SCHEMBL5863641 | 0.84 | LTA4H (0.54) | LTA4HHRH3CACNA1BCACNA1HKCNH2 | |
| SCHEMBL5863794 | 0.83 | LTA4H (0.46) | LTA4HHRH3CACNA1BKCNH2PSMB1 | |
| SCHEMBL5864259 | 0.81 | MCHR1 (0.55) | LTA4HHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL5863669 | 0.81 | PSMB1 (0.49) | LTA4HHRH3KCNH2PSMB1PSMB5 | |
| SCHEMBL5863815 | 0.80 | HIF1A (0.45) | LTA4HHRH3 | |
| SCHEMBL5863688 | 0.80 | RAB9A (0.52) | — | |
| SCHEMBL7264789 | 0.80 | HRH3 (0.50) | LTA4HHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1542967-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026823-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | LTA4H 1687/4885HRH3 1036/4885CACNA1B 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.